Alkermes plc

ALKS Healthcare Drug Manufacturers Specialty & Generic

Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024. In the quarter to June 2026, revenue grew 27.0%, EPS fell 99.4% and free cash flow grew 1.13%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

41.22 1.12 +2.79%
Market cap
$6.7B
P/E
102×
Fwd P/E
−108×
Dividend yield
—
F-score
7/9
Altman Z
5.33
Beneish M
−3.29
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

22.40% 14.72% 9.36% 3.85%
Piotroski F-Score
8 7 4 3
ROA
15.11% 10.64% 4.82% 1.99%
ROIC
36.01% 31.75% 4.36% 2.76%
Return on Tangible Assets
22.38% 15.03% 15.59% 6.13%
Average Days of Receivables
85.03 82.61 95.23 99.91
Free Cash Flow per Share
2.97 2.92 1.33 1.33
Free Cash Flow
490.91 481.42 221.18 222.71
Capital Expenditures
(50.17) (39.33) (35.02) (28.47)
Other line items
Cash ROIC
17.26% 15.34% 5.86% 5.61%
Accounts Receivable Turnover
4.22 4.11 4.30 4.11
Accounts Payable Turnover
1.13 0.83 0.87 0.89
Inventory Turnover
1.11 1.04 0.80 1.05
Average Days of Payables
369.50 537.99 511.36 471.29
Days of Inventory on Hand
328.28 365.31 588.48 423.78
Tax Rate
(0.16) (0.17) (0.25) (0.32)
Research and Development Expense of Revenue
19.00% 21.95% 22.75% 23.45%
Selling, General and Administrative Expense of Revenue
43.47% 47.53% 50.85% 50.44%
Share Based Compensation of Revenue
6.13% 6.69% 7.18% 7.10%
Interest Coverage
— — 5.12 2.04
Operating CF/Net income
1.60 2.15 1.68 3.80
Depreciation/Fixed assets
0.12 0.12 0.24 0.48
Capex/Depreciation
(1.66) (1.45) (0.67) (0.27)
Revenue per Share
9.22 8.96 9.40 9.98
Operating CF per Share
3.28 3.16 1.54 1.50
Capex per Share
(0.30) (0.24) (0.21) (0.17)
Capex to Sales
0.03 0.03 0.02 0.02

Fold the line items

Columns are period end dates